Stealth BioTherapeutics (NASDAQ: MITO recently presented positive results from its ophthalmic programs in dry age-related macular degeneration (AMD) and Leber's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE